Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Beam Therapeutics Inc
(NQ:
BEAM
)
24.31
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1
Open
24.31
Bid (Size)
24.00 (1)
Ask (Size)
25.11 (2)
Prev. Close
24.31
Today's Range
24.31 - 24.31
52wk Range
16.95 - 49.50
Shares Outstanding
79,199,501
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Popular Crypto Trader Shares 2024 Predictions For These Three Altcoins
April 12, 2024
Popular pseudonymous crypto analyst Altcoin Sherpa on Friday shared his insights on three altcoins: Beam (CRYPTO: BEAM), Arbitrum (CRYPTO: ARB), and Render (CRYPTO:
Via
Benzinga
Gene Therapy Side Effects: Verve Therapeutics Halts Enrollment Of Lead Gene Therapy Trial In Patients With Bad Cholesterol
April 02, 2024
Verve Therapeutics' latest update on the Heart-1 Phase 1b trial of VERVE-101. Explore VERVE-102's development and regulatory clearances for the Heart-2 clinical trial, offering hope for patients with...
Via
Benzinga
Performance
YTD
-11.31%
-11.31%
1 Month
-28.64%
-28.64%
3 Month
+0.75%
+0.75%
6 Month
+16.87%
+16.87%
1 Year
-21.83%
-21.83%
More News
Read More
Expert Outlook: Beam Therapeutics Through The Eyes Of 4 Analysts
March 27, 2024
Via
Benzinga
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
March 26, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Navigating 4 Analyst Ratings For Beam Therapeutics
February 28, 2024
Via
Benzinga
Recap: Beam Therapeutics Q4 Earnings
February 27, 2024
Via
Benzinga
MarketBeat Week in Review – 3/4 – 3/8
March 09, 2024
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Exposures
Artificial Intelligence
Interest Rates
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
March 06, 2024
Via
MarketBeat
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
February 28, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat
February 27, 2024
Via
Investor's Business Daily
Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug
February 27, 2024
Via
Investor's Business Daily
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
February 27, 2024
Via
Benzinga
Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday
February 27, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Beam Therapeutics Inc. (NASDAQ: BEAM) Leading the Way in Tuesday Trading Based on Percentage Gain
February 27, 2024
Via
Investor Brand Network
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
February 27, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Is CRISPR Therapeutics the NVIDIA of gene editing?
February 26, 2024
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
Beam Therapeutics Stock Shows Healthy Relative Strength Improvement
February 16, 2024
Via
Investor's Business Daily
Analysts see over 50% gains in these 2 mid-cap biotech stocks
February 14, 2024
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
COVID-19
Cathie Wood Trims Nvidia, Shopify Stakes To Pump Whopping $40M Into Pinterest Despite Q4 Revenue Miss
February 08, 2024
Via
Benzinga
3 Biotech Stocks to Buy on the Dip: February 2024
February 07, 2024
Via
InvestorPlace
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 05, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Why Beam Therapeutics Stock Zoomed 17% Higher Today
January 29, 2024
Via
The Motley Fool
2 gene editing stocks to keep on your 2024 watchlist
January 23, 2024
Via
MarketBeat
Exposures
Product Safety
Bitcoin, Ethereum, Dogecoin Rise As Investors Weigh Spot ETF Impact: Analyst Says Scenario For King Crypto Is 'Rejection' At $46K And Then Correction To Below $40K
January 16, 2024
Via
Benzinga
Topics
ETFs
Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market
January 16, 2024
Via
InvestorPlace
Exposures
Product Safety
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
